UBS Maintains Neutral on Corteva, Raises Price Target to $89

Benzinga Newsdesk www.benzinga.com Positive 58.4%

Neg 0% Neu 0% Pos 58.4%

UBS analyst Joshua Spector maintains Corteva (NYSE:CTVA) with a Neutral and raises the price target from $86 to $89.

Comments

No comments yet. Be the first!